TABLE 3.
Polymerase variants arising during lamivudine therapya
| Woodchuck | Titer (virions/ml) at indicated time (days) from start of lamivudine treatment
|
|||
|---|---|---|---|---|
| −28 | 178 | 347 | 423 | |
| AD infected | ||||
| 326 | 4.4 × 109 WT | 5 × 106 WT/I | <1 × 106 WT | 2 × 107 WT |
| 328 | 4 × 109 WT | 5 × 107 WT/I | <1 × 106 WT/I | ? |
| 331 | 3.7 × 109 WT | 3 × 107 WT/I | 1.7 × 108 I/? | 6 × 108 I/? |
| 338 | 2.1 × 109 WT | 1.8 × 108 WT | 1.3 × 107 WT/I | 3 × 108 WT/I |
| Mock infected | ||||
| 335 | 3.4 × 109 WT | 1 × 109 WT/I | 1.4 × 108 WT/I | 1 × 108 WT/I/II |
| 336 | 6.4 × 109 WT | 2 × 106 WT/II | 1.8 × 108 II | 5 × 108 II |
| 337 | 6 × 109 WT | 4 × 106 WT/I | 6 × 108 WT/I/II | ND |
| 342 | 4.5 × 109 WT | 1 × 109 WT | 6 × 107 WT/I | 5 × 108 WT/I |
| B domainC domain |
| Wild type543-LAHPFIMGFR KLPMGVGLSP FLLAQFTSAL ASMVRRNFPH CVVFAYMDDL VLGARTSEHL-602 |
| Type I---------- –--------- ---T------ ---------- ---------- ---------- |
| Type II---------- ---------- --MV------ ---------- ---------- ---------- |
a
Genotypes of virus in serum samples were estimated by direct sequencing of PCR products. The second sample (178 days) was collected at the time of adenovirus infection. Variants representing less than 10% of the total will not be detected. Identification of the type II variant is tentative, as the observed sequence could have been produced by a mixture of mutants with the single amino acids changes. WT, wild type; I, type I variant; II, type II variant.